Remodilins for airway remodeling and organ fibrosis

US12281060B2 · kind B2 · utility

Assignees

• THE UNIVERSITY OF CHICAGO · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• President and Fellows of Harvard College · US
• IIT Research Institute · US
• Beth Israel Deaconess Medical Center, Inc. · US

Inventors

• Julian Solway · Glencoe, US
• Nickolai DULIN · Chicago, US
• Diane K. Luci · Germantown, US
• David MALONEY · Point of Rocks, US
• Chan Young Park · Belmont, US
• Jeffrey J. Fredberg · Sharon, US
• David L. MCCORMICK · Chicago, US
• Ramaswamy Krishnan · Cambridge, US

Key dates

• Filing date: Apr 2, 2020
• Grant date: Apr 22, 2025
• Expiry date: Apr 26, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.